Clinical Trials Browser

Phase 1 × atezolizumab × Clear all

NCT06066138 2026-04-16

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Phase 1 Recruiting

DermatologicGastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Sarcoma, Alveolar Soft Part, Small Cell Lung Carcinoma

NCT06496568 2026-04-16

A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab, and Inavolisib Plus Pembrolizumab in PIK3CA-Mutated Cancers

Phase 1 Recruiting

PIK3CA-Mutated Cancers

NCT05581004 2026-04-15

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms

NCT06760481 2026-04-15

Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)

Phase 1 Active not recruiting

Advanced Solid Malignancies

NCT06077500 2026-04-14

DAREONᵀᴹ-8

Phase 1 Active not recruiting

Small Cell Lung Carcinoma

NCT03321643 2026-04-13

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

Phase 1 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05595460 2026-04-13

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

Phase 1 Active not recruiting

SCLC,Extensive Stage

NCT07190833 2026-04-09

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)

Phase 1 Recruiting

Other solid neoplasm

Treatment-Refractory Solid Tumors

NCT04560972 2026-04-07

LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer

Phase 1 Active not recruiting

Extensive Stage Lung Small Cell Carcinoma

NCT06444815 2026-04-07

STEALTH-001

Phase 1 Recruiting

DermatologicGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma, Mesothelioma

NCT07170592 2026-04-07

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients

Phase 1 Not yet recruiting

Other solid neoplasm

Treatment-Refractory Solid Tumors

NCT06031441 2026-04-03

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Locally Advanced Solid Tumors

NCT06179069 2026-04-03

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

Phase 1 Recruiting

SCLC

NCT04303858 2026-04-01

A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors

Phase 1 Completed

Other solid neoplasm

Solid Tumors

NCT06807632 2026-04-01

A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer

Phase 1 Recruiting

Small Cell Lung Carcinoma

NCT04929223 2026-03-31

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Phase 1 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07113691 2026-03-27

TIARA

Phase 1 Recruiting

Recurrence

NCT04432207 2026-03-25

A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer

Phase 1 Terminated

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT04911166 2026-03-24

Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Phase 1 Active not recruiting

Skin Neoplasms

NCT04020809 2026-03-09

Neoadjuvant Atezolizumab in Cutaneous Melanoma

Phase 1 Active not recruiting

Melanoma

NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Phase 1 Active not recruiting

Bites and Stings, Lung Neoplasms

NCT06537310 2026-03-03

A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

Cancer-Neoplasms

NCT06492954 2026-03-02

AflacST2301

Phase 1 Recruiting

Osteosarcoma

NCT06616623 2026-02-27

Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04250155 2026-02-24

An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumors

NCT05488522 2026-02-20

SBRT With Atezo/Bev for HCC

Phase 1 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04919369 2026-02-13

All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04449874 2026-02-12

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Phase 1 Active not recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

NCT05546879 2026-02-10

Liver-NET1

Phase 1 Suspended

Gastrointestinal

Carcinoma, Hepatocellular

NCT04081688 2026-02-05

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

Phase 1 Terminated

16 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06898957 2026-02-05

(DeLLphi-310)

Phase 1 Recruiting

Small Cell Lung Carcinoma

NCT05867121 2026-02-02

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

Phase 1 Active not recruiting

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Stomach Neoplasms

NCT05542407 2026-01-29

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Phase 1 Recruiting

GynecologicOtherSarcoma

Carcinosarcoma, Disease, Neoplasm Metastasis, Obesity, Endometrial Neoplasms

NCT06302426 2026-01-16

Trial of INI-4001 in Patients With Advanced Solid Tumours

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT04109456 2026-01-15

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Phase 1 Completed

Melanoma

NCT05092373 2026-01-14

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Phase 1 Recruiting

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Endometrial Neoplasms

NCT04161755 2026-01-07

Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06488716 2025-12-24

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Solid Tumour

NCT06551142 2025-12-18

PanTumor-101

Phase 1 Recruiting

Neoplasms

NCT06332755 2025-11-24

LB-LR1109

Phase 1 Recruiting

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma

NCT03738228 2025-11-12

Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer

Phase 1 Completed

40 enrolled 17 charts

Uterine Cervical Neoplasms

NCT04196530 2025-11-12

EIK1001

Phase 1 Completed

Neoplasms

NCT03228537 2025-11-10

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

Phase 1 Active not recruiting

28 enrolled 17 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT02599454 2025-10-27

Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT02862275 2025-10-23

Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer

Phase 1 Active not recruiting

Other hematologic neoplasm

Neoplasm Metastasis, Hematologic Neoplasms

NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Phase 1 Active not recruiting

Other solid neoplasmSarcoma

Advanced Solid Tumors

NCT05334329 2025-10-15

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04631029 2025-10-03

Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread

Phase 1 Completed

3 enrolled 12 charts

Brain Neoplasms

NCT04808245 2025-09-22

INTERCEPT-H3

Phase 1 Active not recruiting

Glioblastoma, Glioma